查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1772261

美国男性脱髮症市场规模、份额、趋势分析报告：按治疗、销售管道、性别、最终用途、细分市场预测，2025-2030 年

U.S. Androgenetic Alopecia Market Size, Share & Trends Analysis Report By Treatment (Pharmaceuticals, Devices), By Sales Channel (Prescriptions, OTC), By Gender, By End Use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国男性脱髮症市场的趋势：

预计到 2024 年，美国男性脱髮症市场规模将达到 9.791 亿美元，2025 年至 2030 年的复合年增长率为 6.6%。

男性脱髮症(AGA) 的盛行率不断上升，推动着市场成长。作为最常见的脱髮症，男性脱髮症影响着相当一部分人口，其中老龄化和遗传因素也起着一定作用。随着脱髮预防意识的增强，越来越多的人开始寻求治疗，从而扩大了市场。根据美国国家医学图书馆 2023 年 7 月发布的数据，美国约有 5,000 万名男性和 3,000 万名女性患有男性脱髮症(AGA)。

另一个因素是治疗方案的进步。市场正在见证各种创新治疗方法的推出，例如外用溶液、口服药物以及富血小板血浆 (PRP) 疗法和植髮手术等微创手术。製药公司也加大研发投入，以开发更有效、更方便的治疗方法方法，从而吸引更广泛的消费者群体。

新药核准和市场供应的不断扩大将进一步推动市场成长。 2025年6月，Pelagie Pharmaceuticals宣布了PP405的2a期临床试验的正面结果。 PP405是一种透过重新运作暂停状态毛囊干细胞来治疗掉髮的局部治疗药物。这项进展使Pelagie成为男性脱髮症再生医学领域的领导者。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国男性脱髮症市场变数、趋势与范围

  • 市场展望
    • 母市场展望
    • 相关/支持市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国男性脱髮症市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
  • 美国男性脱髮症市场：通路分析

第四章美国男性脱髮症市场：治疗评估与趋势分析

  • 治疗细分仪表板
  • 美国男性脱髮症市场：治疗差异分析
  • 美国男性脱髮症市场规模及趋势分析（依治疗方法，2018-2030）
  • 製药
  • 装置

第五章美国男性脱髮症市场：最终用途估计与趋势分析

  • 最终用途细分仪表板
  • 美国男性脱髮症市场：最终用途趋势分析
  • 2018-2030年美国男性脱髮症市场规模及趋势分析（依最终用途）
  • 居家照护环境
  • 皮肤科诊所

第六章美国男性脱髮症市场：销售管道评估与趋势分析

  • 销售管道细分仪表板
  • 美国男性脱髮症市场：销售管道变化分析
  • 美国男性脱髮症市场规模及销售管道趋势分析（2018-2030）
  • 处方笺
  • 非处方药

第七章美国男性脱髮症市场：性别估计与趋势分析

  • 男性
  • 女士

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • Key company heat map analysis, 2024
  • 公司简介
    • Johnson &Johnson Services, Inc.
    • Cipla
    • Sun Pharmaceutical Industries Ltd.
    • Merck &Co., Inc
    • Dr. Reddy's Laboratories Ltd.
    • Aurobindo Pharma Limited
    • Hairmax International LLC
    • Freedom Laser Therapy, Inc.（iRESTORE Hair Growth System）
    • Curallux, LLC
    • Apira Science, Inc.（iGROW Laser）
    • Theradome Inc.
Product Code: GVR-4-68040-645-8

U.S. Androgenetic Alopecia Market Trends:

The U.S. androgenetic alopecia market was valued at USD 979.1 million in 2024 and is expected to grow at a CAGR of 6.6% from 2025 to 2030. The increasing incidence of Androgenic Alopecia (AGA) is driving market growth. Androgenetic alopecia, the most common form of hair loss, affects a significant portion of the population, with aging and genetic factors playing a role. As awareness about hair loss solutions rises, more individuals seek treatments, expanding the market. According to data published by the National Library of Medicine in July 2023, approximately 50 million men and 30 million women in the U.S. were affected by androgenetic alopecia (AGA).

Another factor is the advancement in treatment options. The market has witnessed the introduction of innovative therapies, such as topical solutions, oral medications, and minimally invasive procedures such as platelet-rich plasma (PRP) therapy and hair transplant surgeries. Pharmaceutical companies also invest in research and development to create more effective and convenient treatments, attracting a broader consumer base.

The approval of new drugs and the expansion of over-the-counter products further propel market growth. In June 2025, Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405, a topical treatment targeting hair loss by reactivating dormant hair follicle stem cells. This advancement positions Pelage as a leader in regenerative medicine for androgenetic alopecia.

U.S. Androgenetic Alopecia Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the U.S. androgenetic alopecia market report based on treatment, end use, sales channel, and gender:

  • Treatment Outlook (Revenue, USD Million, 2018 - 2030)
  • Pharmaceuticals
  • Devices
  • End Use Outlook (Revenue, USD Million, 2018 - 2030)
  • Homecare Settings
  • Dermatology Clinics
  • Sales Channel Outlook (Revenue, USD Million, 2018 - 2030)
  • Prescriptions
  • OTC
  • Gender Outlook (Revenue, USD Million, 2018 - 2030)
  • Male
  • Female

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End Use
    • 1.2.3. Sales Channel
    • 1.2.4. Gender
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Sales Channel Outlook
    • 2.2.4. Gender Outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Androgenetic Alopecia Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. U.S. Androgenetic Alopecia Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political Landscape
      • 3.3.2.2. Technological Landscape
      • 3.3.2.3. Economic Landscape
  • 3.4. U.S. Androgenetic Alopecia Market: Pipeline Analysis

Chapter 4. U.S. Androgenetic Alopecia Market: Treatment Estimates & Trend Analysis

  • 4.1. Treatment Segment Dashboard
  • 4.2. U.S. Androgenetic Alopecia Market: Treatment Movement Analysis
  • 4.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Pharmaceuticals
    • 4.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 4.5. Devices
    • 4.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 5. U.S. Androgenetic Alopecia Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Segment Dashboard
  • 5.2. U.S. Androgenetic Alopecia Market: End Use Movement Analysis
  • 5.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Homecare Settings
    • 5.4.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 5.5. Dermatology Clinics
    • 5.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Androgenetic Alopecia Market: Sales Channel Estimates & Trend Analysis

  • 6.1. Sales Channel Segment Dashboard
  • 6.2. U.S. Androgenetic Alopecia Market: Sales Channel Movement Analysis
  • 6.3. U.S. Androgenetic Alopecia Market Size & Trend Analysis, by Sales Channel, 2018 to 2030 (USD Million)
  • 6.4. Prescriptions
    • 6.4.1. Market Estimates and Forecasts 2018 to 2030 (USD million)
  • 6.5. OTC
    • 6.5.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Androgenetic Alopecia Market: Gender Estimates & Trend Analysis

  • 7.1. Male
    • 7.1.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)
  • 7.2. Female
    • 7.2.1. Market Estimates and Forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Johnson & Johnson Services, Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Cipla
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Sun Pharmaceutical Industries Ltd.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Merck & Co., Inc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Dr. Reddy's Laboratories Ltd.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Aurobindo Pharma Limited
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Hairmax International LLC
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Freedom Laser Therapy, Inc. (iRESTORE Hair Growth System)
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Curallux, LLC
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Apira Science, Inc. (iGROW Laser)
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives
    • 8.4.11. Theradome Inc.
      • 8.4.11.1. Company overview
      • 8.4.11.2. Financial performance
      • 8.4.11.3. Product benchmarking
      • 8.4.11.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. androgenetic alopecia market, by treatment, 2018 - 2030 (USD Million)
  • Table 3 U.S. androgenetic alopecia market, by end use, 2018 - 2030 (USD Million)
  • Table 4 U.S. androgenetic alopecia market, by sales channel, 2018 - 2030 (USD Million)
  • Table 5 U.S. androgenetic alopecia market, by gender, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. androgenetic alopecia market: market outlook
  • Fig. 10 U.S. androgenetic alopecia competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. androgenetic alopecia market driver impact
  • Fig. 16 U.S. androgenetic alopecia market restraint impact
  • Fig. 17 U.S. androgenetic alopecia market strategic initiatives analysis
  • Fig. 18 U.S. androgenetic alopecia market: Treatment movement analysis
  • Fig. 19 U.S. androgenetic alopecia market: Treatment outlook and key takeaways
  • Fig. 20 Pharmaceuticals market estimates and forecast, 2018 - 2030
  • Fig. 21 Devices market estimates and forecast, 2018 - 2030
  • Fig. 22 U.S. androgenetic alopecia market: End Use movement analysis
  • Fig. 23 U.S. androgenetic alopecia market: End Use outlook and key takeaways
  • Fig. 24 Homecare settings market estimates and forecasts, 2018 - 2030
  • Fig. 25 Dermatology clinics market estimates and forecasts, 2018 - 2030
  • Fig. 26 U.S. androgenetic alopecia market: Sales channel movement analysis
  • Fig. 27 U.S. androgenetic alopecia market: Sales channel outlook and key takeaways
  • Fig. 28 Prescriptions market estimates and forecasts, 2018 - 2030
  • Fig. 29 OTC market estimates and forecasts, 2018 - 2030
  • Fig. 30 U.S. androgenetic alopecia market: Gender movement analysis
  • Fig. 31 U.S. androgenetic alopecia market: Gender outlook and key takeaways
  • Fig. 32 Male market estimates and forecasts, 2018 - 2030
  • Fig. 33 Female market estimates and forecasts, 2018 - 2030